NCT02754076已完成1 期
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intracerebroventricular AX 250 in Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)
Allievex Corporation7 个研究点 分布在 7 个国家目标入组 23 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 7
- 主要终点
- Safety Evaluation of weekly infusions of AX 250 (Part 1 & Part 2) - Number of participants with abnormal clinical laboratory values and/or Adverse Events that are related to treatment.
研究概览
简要总结
The study's primary objectives are to evaluate the safety and tolerability of AX 250 administered to subjects with MPS IIIB via an ICV reservoir and catheter and to evaluate the impact of AX 250 on cognitive function in patients with MPS IIIB as assessed by the Development Quotient.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals eligible to participate in Part 1 of this study must meet all of the following criteria:
- •Has deficient NAGLU enzyme activity at Screening. Blood for NAGLU enzyme activity will be collected and analyzed centrally.
- •Is ≥ 1 and < 11 years of age (at least 1 of the 3 subjects in Part 1 must be ≥ 1 and < 6 years of age)
- •Has presented with signs/symptoms consistent with MPS IIIB; for individuals who have not presented with signs/symptoms of disease (eg, siblings of known patients), the determination of eligibility will be at the discretion of the BioMarin medical monitor in conjunction with the site investigator.
- •Written informed consent from parent or legal guardian and assent from subject, if required
- •Has the ability to comply with protocol requirements, in the opinion of the investigator
- •Individuals eligible to participate in Part 2 of this study must meet all of the following criteria:
- •Participated in and met protocol requirements for transitioning from Study 250-901 or participated in Part 1 of Study 250-201
- •Written informed consent from parent or legal guardian and assent from subject, if required
排除标准
- •Individuals who meet any of the following exclusion criteria are ineligible to participate in Part 1 of the study:
- •Has received stem cell, gene therapy or ERT for MPS IIIB
- •Has contraindications for neurosurgery (eg, congenital heart disease, severe respiratory impairment, or clotting abnormalities)
- •Has contraindications for MRI scans (eg, cardiac pacemaker, metal fragment or chip in the eye, or aneurysm clip in the brain)
- •Has a history of poorly controlled seizure disorder
- •Is prone to complications from intraventricular drug administration, including patients with hydrocephalus or ventricular shunts
- •Has received any investigational medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
- •Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data.
- •Is pregnant at any time during the study
- •Individuals who meet any of the following exclusion criteria are ineligible to participate in Part 2 of this study:
- •Has received stem cell, gene therapy or ERT for MPS IIIB
- •Has contraindications for neurosurgery (eg, congenital heart disease, severe respiratory impairment, or clotting abnormalities)
- •Has contraindications for MRI scans (eg, cardiac pacemaker, metal fragment or chip in the eye, or aneurysm clip in the brain)
- •Is prone to complications from intraventricular drug administration, including patients with hydrocephalus or ventricular shunts
- •Has received any investigational medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
- •Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data.
- •Is pregnant at any time during the study
研究组 & 干预措施
AX 250
Experimental
In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
干预措施: AX 250 (Drug)
结局指标
主要结局
Safety Evaluation of weekly infusions of AX 250 (Part 1 & Part 2) - Number of participants with abnormal clinical laboratory values and/or Adverse Events that are related to treatment.
时间窗: Entire study period, up to 124 weeks
Number of participants with abnormal clinical laboratory values and/or Adverse Events that are related to treatment.
Development Quotient (DQ) as efficacy variable with analysis of rate of change of DQ score on treatment vs. rate of change of DQ score prior to treatment.
时间窗: Assessed at study end, up to 124 weeks. Collected at: Part 1 - Baseline; Part 2 - Weeks 12, 24, 36, & 48
次要结局
- Characterize maximum concentration (Cmax) of AX 250 in cerebrospinal fluid (CSF) and plasma as relevant through completion of Part 1 and Part 2(Study end, up to 124 weeks. Collected at: Pre-dose, 0, 4, 10, 24, 48, 72, 96, 168 hours post-dose for the first dose during each dose escalation in Part 1. Pre-dose, 0, 4, 10, 24, 48, 72, 96, 168 hours post-dose for Baseline, Weeks 5, 12, 36 in Part 2.)
- Evaluate GAG levels in plasma(Assessed at study end, up to 124 weeks. Collected at: Each weekly visit as relevant through completion of Part 1 and Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, as relevant in Part 2)
- Evaluate the impact of AX 250 treatment on brain structure assessed by magnetic resonance imaging (MRI)(Assessed at study end, up to 124 weeks. Part 1 - Screening and Baseline; Part 2 - Screening, Baseline, Week 24, and Week 48)
- Characterize area under concentration curve (AUC) of AX 250 in cerebrospinal fluid (CSF) and plasma as relevant through completion of Part 1 and Part 2(Study end, up to 124 weeks. Collected at: Pre-dose, 0, 4, 10, 24, 48, 72, 96, 168 hours post-dose for the first dose during each dose escalation in Part 1. Pre-dose, 0, 4, 10, 24, 48, 72, 96, 168 hours post-dose for Baseline, Weeks 5, 12, 36 in Part 2.)
- Evaluate GAG levels in cerebrospinal fluid (CSF)(Assessed at study end, up to 124 weeks. Collected at: Each weekly visit as relevant through completion of Part 1 and Part 2)
- Characterize immunogenicity of AX 250 total anti-drug anti-body (TAb) in cerebrospinal fluid (CSF) and serum as relevant through completion of Part 1 and Part 2(Assessed at study end, up to 124 weeks. Collected at: First dose during each dose escalation in Part 1, and Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 in Part 2)
- Evaluate GAG levels in urine(Assessed at study end, up to 124 weeks. Collected at: Each weekly visit as relevant through completion of Part 1 and Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, as relevant in Part 2)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT02014558Astellas Pharma Global Development, Inc.265
已完成
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsAdvanced MalignanciesMetastatic CancerNCT02923349Incyte Biosciences International Sàrl87
已完成
2 期
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell CarcinomaBasal Cell CarcinomaNCT04669808Sirnaomics32
已完成
1 期
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisNCT01191996Innate Immunotherapeutics34
已完成
1 期
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerColorectal Cancer MetastaticNCT03531632MacroGenics38